Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3041658 in Moderate-to-Severe Hidradenitis Suppurativa
NCT04493502Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 2
01
Overview
A Phase 2 trial of eltrekibart in hidradenitis suppurativa (HS), sponsored by Eli Lilly and Company. Started Aug 2020; status: completed.
02
Drugs
eltrekibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04493502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493502.